YAP-TEAD Pathway as a Mediator of PPARα-Induced Hepatomegaly: Insights from WY-14643 Studies in Murine Models

Study Background and Research Question

Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor central to lipid metabolism, inflammation modulation, and energy homeostasis. Pharmacological activation of PPARα, notably via selective agonists such as WY-14643 (Pirinixic Acid), has been instrumental in metabolic disorder research and in probing mechanisms of hepatic regeneration. While prior studies have established PPARα’s role in metabolic regulation and anti-inflammatory responses, the downstream molecular pathways linking PPARα activation to liver growth and regeneration remained incompletely defined. The present study directly addresses whether the YAP-TEAD signaling axis is required for PPARα-driven hepatomegaly and hepatic regenerative responses in mice, aiming to clarify the interplay between metabolic and proliferative signaling in the liver [source_type: paper][source_link: N/A].

Key Innovation from the Reference Study

The central innovation of this research lies in demonstrating that the YAP-TEAD transcriptional complex is essential for mediating hepatomegaly and regenerative responses induced by PPARα activation. Using a combination of genetic and pharmacological models, the authors show that administration of WY-14643 upregulates YAP-TEAD activity in the liver, and that disruption of this pathway—via verteporfin (a YAP-TEAD inhibitor), shRNA, or genetic ablation—abolishes the hepatomegaly and regenerative effects otherwise seen with PPARα agonism. This mechanistic insight bridges nuclear receptor signaling with classical proliferative and organ size control pathways, offering a nuanced view of how metabolic cues are integrated into regenerative biology [source_type: paper][source_link: N/A].

Methods and Experimental Design Insights

The study employed rigorous in vivo experiments featuring multiple mouse models:

• Wild-type C57BL/6 mice received daily intraperitoneal injections of WY-14643 (100 mg/kg) or vehicle (corn oil) for 10 days to assess hepatomegaly and serum/liver biochemistry.
• Liver-specific PPARα knockout (PparaΔHep) and floxed controls (Pparafl/fl) were used to confirm the necessity of hepatic PPARα for WY-14643-induced effects.
• Liver-specific YAP knockout (YapΔHep) and floxed controls, as well as AAV-mediated YAP knockdown, allowed interrogation of YAP’s role downstream of PPARα activation.
• Partial hepatectomy (PHx) models evaluated regeneration, with treatments administered post-surgery and tissue/serum collected at defined time points.
• Pharmacological blockade of YAP-TEAD with verteporfin enabled distinction between general and YAP-specific effects.
• Histological analysis (H&E staining), immunohistochemistry (KI67, β-catenin), and quantitative PCR provided cellular, molecular, and functional endpoints.

All animal procedures followed institutional ethical standards [source_type: paper][source_link: N/A].

Protocol Parameters

• assay: WY-14643 administration | value_with_unit: 100 mg/kg/day, i.p. | applicability: Mouse models of hepatomegaly, liver regeneration | rationale: Established dose for robust hepatic PPARα activation in vivo | source_type: paper [source_link: N/A]
• assay: Partial hepatectomy | value_with_unit: Standard 2/3 PHx | applicability: Evaluation of regenerative capacity | rationale: Gold-standard model for liver regeneration studies | source_type: paper [source_link: N/A]
• assay: YAP-TEAD inhibition (verteporfin) | value_with_unit: 100 mg/kg/day, i.p. | applicability: Dissection of YAP dependency | rationale: Pharmacological validation of YAP-TEAD involvement | source_type: paper [source_link: N/A]
• assay: Tissue fixation and histology | value_with_unit: 10% formalin; paraffin-embedding | applicability: Morphometric and proliferation analysis | rationale: Standardized protocols for liver tissue assessment | source_type: paper [source_link: N/A]
• assay: Quantitative real-time PCR | value_with_unit: ∆∆Ct method | applicability: mRNA expression profiling | rationale: Quantitative measurement of gene induction | source_type: paper [source_link: N/A]
• assay: WY-14643 solubility | value_with_unit: ≥16.2 mg/mL in DMSO, ≥48.8 mg/mL in ethanol (with ultrasonic assistance) | applicability: In vitro/in vivo formulation | rationale: Ensures accurate dosing and reproducibility | source_type: product_spec [source_link: https://www.apexbt.com/wy-14643-pirinixic-acid.html]

Core Findings and Why They Matter

Administration of WY-14643 robustly increased liver size and hepatocyte proliferation in wild-type mice, as evidenced by morphometric analysis and KI67 staining. These effects were absent in liver-specific PPARα knockout animals, confirming the requirement for hepatic PPARα. Importantly, the study found that genetic or pharmacological disruption of YAP-TEAD signaling completely nullified WY-14643-induced hepatomegaly and regenerative proliferation, establishing YAP-TEAD as a necessary downstream effector of PPARα in the liver. These findings are significant because they clarify a previously uncharacterized connection between metabolic receptor activation and proliferative signaling, with potential implications for therapeutic liver regeneration, metabolic disorder research, and the controlled modulation of organ size [source_type: paper][source_link: N/A].

Comparison with Existing Internal Articles

Several internal resources discuss the role of WY-14643 in metabolic and inflammatory research:

• WY-14643: Selective PPARα Agonist for Metabolic Research highlights the compound’s use in dissecting metabolic and inflammatory pathways in both cellular and animal models, but does not address the YAP-TEAD axis or regenerative biology.
• WY-14643: Selective PPARα Agonist Empowering Metabolic Re... emphasizes robust anti-inflammatory and insulin-sensitizing effects, supporting the molecule’s use in metabolic disorder and insulin sensitivity enhancement studies.
• WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Me... provides a broad overview of the compound’s utility for inflammation and tumor microenvironment studies.

The reference study extends these established applications by positioning WY-14643 as a key tool for probing liver-specific proliferative mechanisms and the molecular basis of hepatic regeneration, thus bridging metabolic regulation with regenerative biology.

Limitations and Transferability

While the findings robustly demonstrate the necessity of YAP-TEAD in PPARα-induced liver growth in mice, several limitations must be acknowledged:

• The high dose of WY-14643 (100 mg/kg) used in this study may not directly translate to human or other species’ physiology [source_type: workflow_recommendation][source_link: https://www.apexbt.com/wy-14643-pirinixic-acid.html].
• The molecular mechanisms underlying PPARα-to-YAP-TEAD signaling relay remain to be fully delineated, particularly in pathological contexts such as fibrosis or cancer.
• Potential off-target or systemic metabolic effects at high agonist doses warrant careful interpretation and follow-up studies.
• Translation to human liver regeneration or disease models requires further validation.

Overall, the study provides a rigorous foundation for future research on metabolic-liver regeneration cross-talk, but caution is advised when extrapolating to clinical or non-hepatic settings.

Research Support Resources

To facilitate similar investigations into PPARα-driven hepatic and metabolic pathways, researchers can employ WY-14643 (Pirinixic Acid) (SKU A4305), a potent and selective PPARα agonist with validated solubility and formulation properties for in vivo and in vitro work [source_type: product_spec][source_link: https://www.apexbt.com/wy-14643-pirinixic-acid.html]. Its established use in studies of lipid metabolism regulation, insulin sensitivity enhancement, and as an anti-inflammatory agent in endothelial cells makes it a versatile reagent for metabolic disorder research. For protocol optimization, refer to product and workflow guidelines for dosing, solubility, and storage.